<DOC>
	<DOCNO>NCT00048100</DOCNO>
	<brief_summary>Objectives : 1 . Determine toxicity infusion allogeneic donor lymphocyte activate acute leukemia derive dendritic cell ( DC/ADL ) relapse patient allo-stem cell transplant . 2 . Quantitate alloreactivity DC/ADL circulate immune effector cell patient infusion . 3 . Assess efficacy acute myelogenous leukemia ( AML ) Chronic Myelogenous Leukemia Blastic Crisis ( CML-BC ) derive dendritic cell activate lymphocyte promote sustain remission patient relapse allo-BMT stem cell transplant .</brief_summary>
	<brief_title>Anti-Leukemic Dendritic Cell Activated Donor Lymphocytes</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<criteria>AML ( type except M3 ) CIVIL blast crisis great equal 20 % bone marrow blast time relate donor marrow stem cell transplantation relapse post transplant . Willing undergo skin biopsy either leukodepletion apheresis additional marrow aspiration . Stem cell marrow donor willing apheresis TCell collection . Written voluntary inform consent must obtain patient donor . Medical , social psychologic factor would prevent patient receive cooperate full course therapy understanding informed consent procedure . AML FrenchAmericanBritish ( FAB ) subtype M3 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Dendritic cell</keyword>
	<keyword>Lymphocytes</keyword>
	<keyword>AML</keyword>
</DOC>